Kaplan. Inositol polyphosphate derivative inhibits Na ϩ transport and improves fluid dynamics in cystic fibrosis airway epithelia.
epithelial Na ϩ channels; fluid absorption CYSTIC FIBROSIS (CF) airway epithelia show hyperabsorption of liquid due to mutations in the gene for the CF transmembrane conductance regulator (CFTR) resulting in Cl Ϫ channel malfunction and dysregulation of Na ϩ absorption through the amiloride-sensitive epithelial Na ϩ channel (ENaC) (23, 45, 46) . ENaC, the rate-limiting step in the regulation of Na ϩ absorption across epithelia, helps maintain airway surface liquid volume/depth (20) . Excess fluid/volume absorption correlates with defects in ENaC regulation and plays a primary role in the reduced mucociliary clearance found in CF airways. Mucus clearance is an important defense mechanism that protects the airways from infections (22) , and defective mucus clearance is associated with the repeated pulmonary infections in CF patients that ultimately result in organ failure.
In CF airway epithelia, ENaC-mediated Na ϩ absorption is increased 100 -300% (2) . Initially, this was attributed to a direct molecular interaction between CFTR and ENaC. However, no such association was found and is unlikely, because the relationship between ENaC activity and CFTR function is reversed in the sweat glands. Recent studies have demonstrated that electrical potential (34) , intracellular Cl Ϫ concentration (24) , or electrical coupling between Cl Ϫ and Na ϩ fluxes (16) could all mediate the inhibition. Therefore, the agents that modulate non-CFTR Cl Ϫ channel activity, such as Ca 2ϩ -activated Cl Ϫ channels in CF tissue, could secondarily regulate ENaC.
Inhibition of Na ϩ flux through ENaC is predicted to completely compensate for the CFTR defect in restoration of airway surface liquid (ASL) in a mathematical simulation of airway epithelial cells (36, 37) . In support of this, amiloride, an extracellular blocker of ENaC, temporarily increased mucociliary clearance in clinical trials (48) . Problematically, the duration of amiloride action in vivo is very brief (15-30 min) , thereby limiting its therapeutic efficacy. This transience is due in part to the diffusion and dilution of effective concentrations of extracellular amiloride. The relatively short half-life of its target, ENaC, in the plasma membrane (40) may also contribute to its brief duration of action.
Some of the Ͼ30 naturally occurring inositol polyphosphates (IPs) and phosphoinositides (18, 28, 32, 42) are ion channel regulators (5, 12-15, 18, 19, 21, 35, 39, 50 -52) . Whereas D-myo-inositol 1,4,5-trisphosphate [Ins(1,4,5)P 3 ], a trigger for [Ca 2ϩ ] i release, is the most widely recognized (17) , inositol tetrakisphosphates also modulate ion channel activities, including Cl Ϫ and K ϩ channels (12, 18, 21, 50) . A particular inositol phosphate, Ins(3,4,5,6)P 4 , targets Cl Ϫ channels in epithelia (5, 13, 14) . IPs are highly charged, thereby making them unlikely to cross membranes. Thus membranepermeant forms have been developed that enable intracellular delivery, which recapitulates the ion channel modulating activity of endogenous IPs (27, 41, 50) .
In contrast to extracellularly acting agents directed against the extracellular domain of ion channel pores, membranepermeant IP analogs modulate ion channel activities from inside the cell. Analogs of slowly metabolized IPs can have an extended duration of action. Therefore, they have the potential for prolonged activity in contrast to the more rapidly eliminated extracellularly active compounds. We previously observed that direct application of a membrane-permeant analog of Ins(3,4,5,6)P 3 , INO-4995 ( Fig. 1) , to human nasal airway epithelia reduced the amiloride-inhibitable basal short-circuit current (I sc ) (49) . This effect was long lasting but reversible after 48 h. In the current study, we investigated the ionic basis for the inhibition of I sc and probed whether it corresponded to therapeutically meaningful changes in fluid flux as assessed from open-circuit fluxes of 22 Na. Thus, in the absence of INO-4995, the mucosa-to-serosa flux of 22 Na across CF airway epithelia was inhibited by amiloride, but this amiloride sensitivity was abolished by INO-4995. INO-4995 had no effects on Na ϩ fluxes across non-CF airway epithelia. These effects of INO-4995 corresponded to slowing of the fluid absorption rate that portend therapeutic efficacy in CF. In related studies in a mouse nasal potential difference (PD) model, INO-4995 lowered abnormal nasal PD in gut-corrected CF mice (8) , further substantiating its therapeutic potential.
METHODS

Materials.
Surgically excised nasal polyps were obtained from volunteers in collaboration with Dr. Bonnie Ramsey at Children's Hospital, Seattle, WA, and Dr. Ludwig Allegra at the Northwest Nasal Sinus Center. The patients provided informed consent before we obtained the tissue specimens. All protocols complied with institutional guidelines of, and were approved by, the Institutional Review Board at Children's Hospital in Seattle. INO-4995, IPs, phosphate/ PM, and other membrane-permeant IP analogs were obtained from SiChem. All other reagents were provided by Sigma-Aldrich unless otherwise indicated.
CF human nasal epithelial (CFHNE) and non-CF nasal epithelial (HNE) cell cultures were cultured and prepared for Ussing studies as described elsewhere (49) .
Monolayer preparation for Ussing studies. Epithelial cells (passage 2 or 3) were prepared for Ussing chamber and fluid transport studies using Snapwell permeable supports (0.4 m pore size; Corning Costar, Cambridge, MA) coated with 1 g/cm 2 Vitrogen. Cells were plated at 10 5 cells/cm 2 in keratinocyte serum-free media. After 2 days, the media were changed to bronchial epithelial growth medium (BEGM), a 1:1 mixture of DMEM (MediaTech/Cellgro, Herndon, VA), and bronchial epithelial basal media (BEBM) (Clonetics/Biowhittaker, Walkersville, MD), with the following supplements: hydrocortisone (0.5 g/ml), insulin (5 g/ml), transferrin (10 g/ml), epinephrine (0.5 g/ml), triiodothyronine (6.5 ng/ml), bovine pituitary extract (52 g/ml), EGF (0.5 ng/ml), all-trans retinoic acid (50 nM, Sigma), penicillin (100 U/ml, Sigma), streptomycin (0.1 mg/ml, Sigma), nonessential amino acids (1ϫ, Sigma), and fatty acid-free bovine serum albumin (3 g/ml, Sigma). Cells were grown in the BEGM for 1 wk, at which point an air-liquid interface (ALI) culture system was initiated (30) . The cells were grown for 2 wk at ALI and fed every other day basolaterally until use in the Ussing chamber (usually 7-10 days).
Ussing chamber studies. Monolayers of HNE and CFHNE were mounted in modified Ussing chambers (Physiological Instruments, San Diego, CA) with the use of a Ringer bicarbonate solution containing (in mM) 115 NaCl, 2.4 K 2HPO4, 0.4 KH2PO4, 1.2 MgCl2, 1.2 CaCl2, 25 NaHCO3, and 10 glucose, unless otherwise indicated. Experiments were carried out at 37°C, and the pH was adjusted to 7.4 by being gassed with 95% O2-5% CO2. After an open-circuit equilibration period of 10 min, the transepithelial PD was recorded, the cells were voltage clamped at 0 mV, and the resulting Isc was continuously recorded. A periodic bipolar voltage pulse monitored resistance calculated using Ohm's law. In acute experiments, drugs were added to the apical or basolateral compartment, as indicated, and the changes in response were recorded. In preincubation experiments, a compound dissolved in 100 l of media was added to the apical surface of monolayers growing on Snapwells. After a 2-h incubation period at 37°C in a CO2 incubator, the apical media containing compound was removed, and monolayers were washed with BEGM and returned to ALI for the indicated time before being mounted in Ussing chambers.
22 Na ϩ flux. Monolayers of CFHNE were pretreated with either 20 M INO-4995 or 2-h vehicle control for 17-22 h before being tested. Monolayers were mounted in Ussing chambers, and PD and resistance were monitored under open-circuit conditions while ion fluxes were measured as described previously (26) . A quantity of 10 Ci of 22 Na and 45 Ci of 36 Cl were added to either the mucosal or serosal chamber. Aliquots (3 ml) were removed from the downhill chambers for counting at 5-min intervals. After 20 min, 100 M amiloride was added to the mucosal chamber and aliquots were removed for an additional 20 min. Ion flux was calculated as described.
Patch clamp. Outside-out patches were configured from 3T3 cells stably expressing rat ␣␤␥-ENaC. Patches from 3T3 containing nearsilent ENaCs were activated with trypsin (4) (23) . Apical nystatin (360 g/ml) was applied to the solution that bathed the apical compartment at the indicated time. Cytosolic levels of Na ϩ (25 mM) were achieved in the bathing solutions by replacing a portion of the NaCl with NMDG-C (145 mM). After permeabilization, the increase in Isc is primarily due to Na ϩ movement driven by the Na ϩ -K ϩ -ATPase that is completely inhibited by basolateral application of 100 M ouabain. The composition of the buffer was as follows (in mM): 145 NMDG-Cl, 25 Na ϩ , 5 K ϩ , 1. 
RESULTS
INO-4995 inhibits sodium flux.
We have previously shown that direct exposure of CF human nasal epithelial (CFHNE) monolayers to INO-4995 results in a progressive decline in amiloride inhibitable I sc . Furthermore, a pulsed exposure to INO-4995 inhibits basal I sc in CF airway epithelia for Ͼ24 h (49). Although I sc reflects the sum of all transepithelial ion flux, the elevated basal I sc in CF tissue is attributed to abnormally high levels of mucosal to serosal Na ϩ absorption (29 Prolonged effects of INO-4995 on CFNHE electrophysiology. We exposed monolayers apically to INO-4995 for 2 h, then washed and returned the cultures to ALI for 22 h before mounting the monolayers in Ussing chambers for testing. At this time, I sc was reduced ( Fig. 2A) , demonstrating a prolonged duration of action. We repeated this experiment with multiple doses of INO-4995 to generate the dose-response curve depicted in Fig. 2B . INO-4995 dose-dependently inhibited the basal I sc in CFHNE (EC 50 ϭ 10 M; Fig. 2B ). In addition to the vehicle controls, additional controls included pretreatment with phosphate PM ester (P i /PM), or structurally related analogs with fewer phosphates. IP analogs that did not have the membrane-permeating protecting groups were likewise without effect. A series of membrane-permeant IP analogs ranged from having no effect to having similar effects to INO-4995 with potency corresponding to the phosphorylation pattern and the nature of the substitutions at positions 1 and 2. INO-4995 had no apparent deleterious effects on tight junction integrity, as resistance did not decrease (Fig. 2C) (Fig. 3) . The majority (91%) of the INO-4995 effect is attributable to the amiloride-inhibitable portion of the current supporting the hypothesis that INO-4995 inhibits ENaC (Fig. 3B) .
The effect of INO-4995 on ENaC activity in outside-out excised patches was measured in 3T3 cells stably overexpressing rat ␣␤␥ ENaC subunits. Before INO-4995 exposure, the channel conductance and sensitivity to block with amiloride confirmed ENaC identity and patch configuration in this expression system (3, 4) . INO-4995 (20 M) applied in the bath inhibited ENaC in this experiment in eight of nine patches but was without effect on unitary current amplitude (data not shown). A representative trace depicting single-channel transitions is depicted in Fig. 3C , and the change in open probability is depicted in Fig. 3 , D and E. 22 Table 1 . Both serosal to mucosal and mucosal to serosal amiloride inhibitable 22 Na ϩ flux were absent in INO-4995-treated monolayers, whereas amiloride inhibited serosal-tomucosal 22 Na flux in untreated cells. These results are consistent with amiloride-sensitive fluid absorption being present normally, but being abolished by treatment with INO-4995.
In well-differentiated CFHNE monolayers, the major pathway for transcellular movement of Na ϩ is apical entry via ENaC and basolateral exit via Na ϩ -K ϩ -ATPase. Consequently, apical application of amiloride (100 M) or basolateral addition of the Na ϩ -K Na ϩ -K ϩ -ATPase contributed to INO-4995 inhibition of basal I sc , we tested the effect of INO-4995 on the ouabain-sensitive current in apically permeabilized monolayers. We monitored spontaneous I sc for 10 min to assess the effect of INO-4995 on amiloride-inhibitable current. As shown in Fig. 4A , a 2-h preincubation with 10 M INO-4995 resulted in a typical decrease of basal current measured 4 h later. Amiloride (100 M) was added to assess the contribution of ENaC to basal I sc . We then exposed the apical surface of CFHNE monolayers to nystatin, a pore-forming antimycotic that enhances permeability to monovalent ions. The Na ϩ -K ϩ -ATPase inhibitor, ouabain, completely inhibited the resulting increase in I sc after apical permeabilization with nystatin. We observed no differences in INO-4995 pretreated monolayers vs. controls after amiloride addition or apical permeabilization. The results show that INO-4995 has little to no effect on ouabain-inhibitable current (Fig. 4) and supports the hypothesis that INO-4995 inhibits basal I sc through modulation of ENaC activity and not Na ϩ -K ϩ -ATPase activity. In a different protocol, we added amiloride after nystatin to determine whether the entire difference in basal I sc between INO-4995-pretreated monolayers and control monolayers could be eliminated by apical permeabilization (Fig. 4B ). Monolayers were exposed to 10 M INO-4995 for 2 h as in Fig. 2 and Ussing chamber recordings carried out 22 h later. We monitored basal I sc for 25 min, whereupon apical addition of nystatin eliminated the difference between INO-4995 pretreated monolayers and controls after a brief period of equilibration, demonstrating that the target of the INO-4995 action was located in the apical membrane. Amiloride had very little effect when added after nystatin, but addition of ouabain brought the I sc to zero, confirming the success of the nystatin permeabilization and demonstrating again that INO-4995 had no apparent effect on Na ϩ -K ϩ -ATPase. To further probe whether there might be an effect of INO-4995 on basolateral K ϩ channel activity, a K ϩ gradient was applied to monolayers apically permeabilized with nystatin after pretreatment with 10 M INO-4995 as in the experiments described above. As shown in Fig. 4C , the current driven by the K ϩ gradient was similar in both INO-4995-treated monolayers and controls.
INO-4995 inhibits fluid absorption.
To ascertain the therapeutic relevance of these electrophysiological observations, we evaluated the ability of compounds to inhibit fluid absorption measured directly. The assay consisted of monolayer cultures of polarized CF nasal epithelia exposed to an apical buffer containing test compounds and a known concentration of the nonpermeable BD, using a modification of a protocol described by Matsui and coworkers (30) . The observed absorption rates ranged from 4 to 6 l⅐cm Ϫ2 ⅐h
Ϫ1
, consistent with values reported for CF tissue elsewhere (20) . We used amiloride, a blocker of the Na ϩ channel, ENaC, to assess the ability of this assay to measure relevant changes in fluid secretion. Accordingly, blocking ENaC with amiloride should significantly reduce fluid absorption. As anticipated, amiloride (continuously present for the duration of the 18-h incubation period) inhibits fluid absorption measured by the BD assay (Fig. 5A ) in a dose-dependent fashion.
We hypothesized that because INO-4995 blocks Na ϩ flux, it would inhibit fluid absorption. Testing this, we exposed welldifferentiated monolayer cultures of CFHNE to an apically applied buffer containing INO-4995 and BD (Fig. 5) . The EC 50 of the effect is ϳ20 M and closely parallels the effect on INO-4995 inhibition of fluid absorption persists for 42 h. The residence time of aerosolized drugs in airways is limited by expulsion, absorption, and hydrolysis. This may contribute to the short duration of action of extracellularly acting agents, such as amiloride or purinergic agonists (38, 54) . In contrast, membranepermeant analogs of IP are not subject to those factors once inside the cell. Therefore, we compared the duration of the effect on fluid absorption following pulsed exposure to compounds. We compared the long-term effect of pulsed exposure to 50 M INO-4995 (Fig. 5C) to that of amiloride. The data show that INO-4995 exerted prolonged effects on fluid absorption. After a 2-h exposure, INO-4995 continues to affect fluid levels up to 42 h after exposure. In contrast, amiloride effects are short lived, vanishing on removal from surface liquid so that, as expected, no residual effect of amiloride contact is detectable 42 h after exposure (Fig.  5C ). On the basis of these results, INO-4995 is likely to be a much more effective therapeutic than amiloride due to prolonged duration of action.
DISCUSSION
An increase in basal I sc is a characteristic of CF airway epithelia that has been linked to Na ϩ hyperabsorption, reduced ASL fluid levels, and disease severity (20, 23, 30) . Herein we have demonstrated that a prodrug based on a derivative of Ins(3,4,5,6)P 4 , INO-4995, reduces basal I sc , Na ϩ flux, and fluid absorption in human CF nasal epithelia. This effect was specific for CF tissue since INO-4995 had very little effect on I sc in non-CF tissue. The inhibition is dose dependent and long lasting. INO-4995 blocked fluid absorption and I sc with similar dose dependency, suggesting that the effects on Na ϩ , I sc , and fluid absorption are interrelated. The potency of a transient INO-4995 does not act in the same manner as amiloride. First, while amiloride acts extracellularly, INO-4995 acts intracellularly. Second, amiloride action is short-lived and dependent on the continuous presence of the compound, whereas INO-4995 action is prolonged. Third, amiloride potency in normal HNE is similar to that in CFHNE. In contrast, INO-4995 is much more potent in CFHNE than in epithelia from non-CF donors.
INO-4995 reduced the rate of amiloride-inhibitable fluid reabsorption in CF epithelia using a BD assay. There was a component of the fluid absorption rate that was neither inhibited by amiloride nor INO-4995. This may reflect evaporative loss or an uncharacterized conductance. However, the maximum change in the rate of fluid flux with amiloride in the BD assay (2.5 l⅐cm Ϫ2 ⅐h Ϫ1 ) is very close to the amiloride-inhib- itable flux calculated from the 22 Na flux studies (3.3 l ⅐cm Ϫ2 ⅐h Ϫ1 ) assuming isotonicity of transported fluid. Tarran and associates (47) have shown that fluid absorption rates slow when the height of the ASL falls Ͻ20 m. However, under the conditions of the current study, the height of the surface fluid remains well above this level during the entire experiment. Further studies are planned which could determine whether there are differential effects of INO-4995 with varying fluid levels. It should be noted that an amiloride-sensitive fluid absorption of 3 l⅐cm Ϫ2 ⅐h Ϫ1 is similar to that reported by others (20) and, if unopposed, would shrink the depth of ASL by 0.5 m/min. Therefore, if inhibiting amiloride-sensitive Na ϩ absorption unmasks an opposing secretory process, then ASL depth could increase by as much as 0.5 m/min, causing ASL to double in depth approximately every 10 to 20 min.
The key to the therapeutic potential of INO-4995 is its prolonged effect that may be due to slow metabolism of the active form, INO-4913. Ins(3,4,5,6)P 4 levels can remain elevated for hours (50) Fig. 1) , cannot be directly metabolized via this pathway due to the ether-linked octyl group at the 1 position, contributing to its extended duration of its action.
We considered the possibility that INO-4995 could be acting through modulation of serine protease activity, a recently characterized path that modulates ENaC open probability (7). However, INO-4995 appears to act in a serine protease-independent manner because monolayers pretreated with 10 M INO-4995 still exhibited reduced basal I sc relative to control after the addition of trypsin (data not shown). Moreover, the addition of aprotinin, a serine protease inhibitor, further reduced basal I sc in INO-4995 pretreated monolayers in an additive fashion, indicating that the two agents work through separate but complementary mechanisms.
Phosphatidylinositol (PI)3-kinase pathways can regulate ENaC surface expression in renal epithelia. For instance, Nedd4-2 regulates ENaC expression (31, 43, 44) and is downstream of hormone (aldosterone or insulin) triggered serum and glucocorticoid-regulated kinase (Sgk-1) and PI3-kinase signaling (1, 6, 11) . Certain IPs interfere with PI3-kinase signaling pathways (12) and may therefore reverse PI3-kinase-mediated Sgk-1 upregulation of ENaC via Nedd4-2.
INO-4995 may directly modulate ENaC. Herein we have shown that inhibited ENaC open probability in excised outside-out patches. Although the concentration of INO-4995 in the bath was 20 M, the compound would presumably have to cross the patch membrane and be deesterified to generate the active compound, INO-4913, at the site of action. Therefore, a much more detailed study is underway to determine the concentration of the relevant compound and pinpoint the site of action. INO-4995 may indirectly modulate ENaC through actions on Cl Ϫ channels. For instance, INO-4995 is an analog of Ins(3,4,5,6)P 4 , which modulates Ca 2ϩ -activated Cl Ϫ channels in multiple systems (5, 19, 42, 50 -52) . We have shown that an analog of INO-4995 opens Cl Ϫ channels in whole cell patch-clamp configuration (9) , whereas a deesterified form of INO-4995, INO-4913 opens Cl Ϫ channels in a dialyzed cell preparation (10) . In addition, repeated exposure to low doses of INO-4995 enhances the I sc response to ATP, suggesting an increase in Ca 2ϩ -activated Cl Ϫ channel activity (33) . Others have shown that Ca 2ϩ -activated Cl Ϫ channels as well as CFTR activity can modulate Na ϩ flux via electrochemical coupling (16, 24, 25, 34) . A recent study (53) suggests that both ENaC activity and expression levels are modulated by Cl Ϫ channel-mediated changes in intracellular Cl Ϫ levels. However, it is unclear how that mechanism could account for the inhibition of ENaC measured in excised patches described herein.
We have demonstrated that the IP analog, INO-4995, reverses physiological processes associated with pathological function in CF tissue, Na ϩ , and fluid absorption. Thus INO-4995 is a potential treatment for the underlying defect in fluid secretion in CF linked to morbidity and mortality. Our findings support preclinical development of INO-4995 for the treatment of CF and represent the first demonstration of the therapeutic significance of a derivative of an IP signaling molecule. In addition to a potential breakthrough in CF research, our results have much wider implications for the design of pharmaceuticals targeting intracellular IP and phosphoinositide signaling cascades.
